To convert TR3 (Figure 1A, center) into a MUC16-targeted cancer drug, we inserted the entire cDNA of soluble mesothelin (including the N-terminal FLAG tag) to the 5′-terminus of a TR3 expression plasmid (Figure 1A, Meso-TR3). This evidence concerns the gene MSLN and cancer.